Table 3

Exercise capacity and quality of life outcome measures (comparator trials) according to patient disease/condition

Reference	Exercise capacity				Quality of life
	Intervention		Control		Intervention		Control
	Baseline	Post-trial	Baseline	Post-trial	Baseline	Post-trial	Baseline	Post-trial
Pulmonary	6MWT (m)				CRDQ (total score)
Tsai et al 35	363±66	403±82*	383±93	374±136	90±18	99±16*	88±23	90±18
	ESWT (s)				CAT (total score)
	410±253	693±357*†	361±155	316±182	16±7	15±7	15±6	18±6*
	ISWT (m)				PRAISE (total score)
	260±106	275±132	298±114	306±118	46±9	50±6†	46±9	42±10
					FPI-SF (total score)
					66±13	66±14	66±14	66±15
Knox et al 30	ISWT (m)‡				CAT (total score)‡
	159±133	315.63±239.7*†	149±80	202.9±107.8*	24±6.2	18.81±6.85*	25.2±6.6	21.45±5.34*
Hansen et al 28	6MWT (m)				CAT (total score)
	322.3±108.3	8.3 (−7.7 to 24.3)§	332.3±97.5	N/A	19.8±7.3	1.6 (0.1 to 3.3)*†§	20.4±6.6	N/A
					CCQ (total score)
					2.7±0.9	0.2 (−0.1 to 0.5)§	2.9±1.0	N/A
Cardiac	6MWT (m)				MLHFQ (total score)
Peng et al 41	407.09±12.27	419.23±9.67*†	406.05±12.35	406.55±12.54	49.43±12.25	43.11±8.76*†	48.77±12.21	49.20±12.44
Hwang et al 40	6MWT (m)				MLHFQ (total score)
	346±104	364±96	382±106	394±119	47±19	32±19	41±22	35±24
					EQ-5D (VAS)
					62±19	70±17	60±18	70±18
					EQ-5D (utility)
					0.73±0.13	0.73±0.21	0.69±0.26	0.74±0.21
Scalvini et al 42	6MWT (m)‡				N/A
	334±90	449±103.1	354±102	442±97.4
Metabolic	6MWT (m)				N/A
Durturk and Özköslü45	489±143.76	554.39±139*†	458.15±168.87	450.90±165.81*
Hickman et al 46	6MWT (m)¶				SF12v2 (mental)
	448±139	465±125	436±83	425±71	49.7±9.2	52.6±7.9*†	50.5±8.3	48.3±9.1
					SF12v2 (physical)
					48.0±8.1	49.3±8.0	39.8±7.5	42.7±8.4
Baillot et al 44	6MWT (m)				Laval Questionnaire (total score)‡
	488.67±59.99	510±52.53*†	459.67±48.5	472.27±52.27	58.17±14.2	62.69±18	67.12±14.98	68.75±13.49
Neurological	6MWT (m)				N/A
Lai et al 50	334±95	370±90*	373±96	375±116
Fjeldstad-Pardo et al 48	N/A				MFIS (total score)
					47.3±17.8	40.8±20.8	45.5±18.1	32.2±13.3*
Musculoskeletal	N/A				SF-36 (MCS)
Doiron-Cadrin et al 57					44.3±10.2	45.3±10.3	44.3±11.3	43.3±13.3
					SF-36 (PCS)
					36.1±7	35.6±6.2	36.6±6.8	36.2±6.8

All data are reported in mean±SD, unless stated otherwise.
*Reported significant within-group change (p≤0.05).
†Reported significant between-group change (p≤0.05).
‡Data obtained via author contact.
§MD (95% CI) postintervention adjusted.
¶Postintervention assessments conducted by participants unsupervised at home.
CAT, COPD Assessment Task; CCQ, Clinical COPD Questionnaire; CRDQ, Chronic Respiratory Disease Questionnaire; EQ-5D, EQ-5D Questionnaire; ESWT, Endurance Shuttle Walk Test; FPI-SF, Functional Performance Inventory Short Form; ISWT, Incremental Shuttle Walk Test; MCS, Mental Composite Score; MD, difference in means; MFIS, Modified Fatigue Impact Scale; MLHFQ, Minnesota Living With Heart Failure Questionnaire; 6MWT, 6 min Walk Test; N/A, not available; PCS, Physical Composite Score; PRAISE, Pulmonary Rehabilitation Adapted Index of Self-Efficacy Tool; SF-36, 36-Item Short Form Survey; SF12v2, Short Form 12 Item V.2 Health Survey.